There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|June 24||Weekly Loss||My Watchlist|
Phoenix New Media
Barnes & Noble
Pain Therapeutics hurt its shareholders after regulators failed to approve a flagship drug. Public details are scarce given Pfizer's
FSI International shed nearly a quarter of its value after the maker of capital equipment for the microelectronics industry posted quarterly results that were light in terms of revenue. FSI also didn't help its cause by cranking out disappointing near-term guidance.
Phoenix New Media hit a new all-time low last week, though that's not saying much since the Chinese dot-com went public just last month. In its first quarterly report as a public company, Phoenix Media posted revenue growth of 77%. That's impressive, but what isn't so hot is that its gross profit and adjusted earnings only grew by less than a third of that top-line rate.
Investors threw the book at Barnes & Noble after another horrendous quarter. The bibliophile superstore posted a wider-than-expected loss, as it continues to invest in its fledgling Nook platform. Same-store sales fell during the period, validating the bearish knocks on print publishing as a fading industry. This report isn't bleak enough to scare away potential buyers, but it should be enough to motivate B&N to not get too greedy.
Active Network may have been added to the Russell 2000 last week, but investors were still unloading shares of the Web-based platform for managing registrations for activities and events. I had my doubts when Active Network went public last month. Top-line growth is decelerating, losses are mounting, and the model is vulnerable. I'm not patting myself on the back, though, since the stock is now essentially back to where it was when I went off on my bearish rant.
It was a rough week for these five stocks. Let's see which ones bounce back this week.
Which of these five stocks do you think bottomed out last week? Share your thoughts in the comment box below.
Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Longtime Fool contributor Rick Munarriz enjoys cheering on winners and whispering words of encouragement to the losers. He does not own shares in any of the companies in this story. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.